Jim Mellon, Juvenescence Chairman, explains why investing in longevity has the potential to deliver significant financial, personal and humanitarian returns.
“There’s a lot of great stuff happening, but it’s not one drug that’s going to keep you alive another 10 years in good health, it’s going to be a combination of therapies,” he adds. “And if we can get two or three of those therapies out of clinical trials and into the market, then we’re going to have a very big business indeed and we’re pretty confident we’re going to get there.”
